$VRAY News

Last published 3y ago

3y agoBURU CEAD VRAYNUBURU Appoints Brian Knaley as new CEOBusiness WireNUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief
3y agoVRAYViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsPR NewswireDENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC
3y agoVRAYViewRay® Files Voluntary Chapter 11 PetitionsPR NewswireDebtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries
3y agoVRAYVA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy SystemPR NewswireFirst cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER, June 13, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the VA
3y agoVRAYViewRay, Inc. (VRAY) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoVRAYViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingPR Newswire50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER, May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the company's MRIdian MRI-guided
3y agoVRAYViewRay Announces First Quarter 2023 ResultsPR NewswireDENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the
3y agoVRAYViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023PR NewswireDENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday,
3y agoVRAYViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder ValuePR NewswireDENVER, April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The
3y agoVRAYViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023PR NewswireDENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786.
3y agoVRAYMilitary University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer PatientsPR NewswireFirst and only MRIdian in the Czech Republic to bring advanced MRI-guided radiation therapy to the region DENVER, March 7, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced the Czech Ministry of Health has
3y agoVRAYSiteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian® MRI-Guided Radiation TherapyPR NewswireWorld's first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER, March 2, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY)
3y agoVRAYViewRay Announces Fourth Quarter and Full Year 2022 ResultsPR NewswireDENVER, Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights
3y agoVRAYViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023PR NewswireDENVER, Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of fourth quarter 2022 financial results.
3y agoVRAYViewRay Enters into Cooperation Agreement with Hudson Executive CapitalPR NewswireCLEVELAND, Jan. 20, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and
3y agoVRAYFindings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate CancerPR NewswireMIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER, Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY)
3y agoAXGN MIRO VRAYViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial OfficerPR NewswireDENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary
3y agoVRAYChindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer TreatmentPR NewswirePurchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that Chindex Medical Limited
3y agoVRAYUniversity Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® SystemsPR NewswireImmediate order of one system with ability to purchase an additional three systems DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center
3y agoVRAYViewRay Expands Access to Non-Dilutive Capital With New Debt FacilityPR NewswireFacility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million DENVER, Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today
3y agoVRAYViewRay® to Participate in the 34th Annual Piper Sandler Healthcare ConferencePR NewswireDENVER, Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer,
4y agoVRAYViewRay® to Present at the Stifel 2022 Healthcare ConferencePR NewswireDENVER, Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach
4y agoVRAYViewRay Announces Third Quarter 2022 ResultsPR NewswireDENVER, Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Total revenue for
4y agoVRAYMIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate CancerPR NewswireFinal outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022 DENVER, Oct. 27, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the
4y agoVRAYViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer PatientsPR NewswireStudy's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART DENVER, Oct. 24, 2022 /PRNewswire/ --
4y agoVRAYMRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022PR NewswireClinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies DENVER, Oct. 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that the company's MRIdian® MRI-Guided
4y agoVRAYViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation TherapyPR NewswireProspective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone DENVER,
4y agoVRAYViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022PR NewswireDENVER, Oct. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of third quarter 2022 financial results. ViewRay will hold a conference call to discuss results on
4y agoVRAYSUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer PatientsPR NewswireBecomes First Cancer Center in Upstate New York to offer the Advanced Precision of MRIdian® MRI-Guided Radiation Therapy DENVER, Oct. 6, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that SUNY Upstate Cancer Center in Syracuse, Ne
4y agoVRAYSan Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation TherapyPR NewswireItalian hospital reaches patient milestone in less than three years using MRIdian's real-time, on-table adaptive capabilities DENVER, Oct. 4, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that San Pietro Fatebenefratelli Hospital in
4y agoVRAYViewRay to host Investor DayPR NewswireDENVER, Oct. 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022, at 8:00 a.m. Eastern Time in New York City, NY. The event will feature presentations from the ViewRay leaders
4y agoVRAYMD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy ProgramPR NewswireFirst MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston DENVER, Sept. 20, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that the University of Texas MD Anderson Cancer Center in Houston,
4y agoVRAYViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare ConferencePR NewswireDENVER, Sept. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Fi
4y agoVRAYGenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four SystemsPR NewswireNew agreement expands access to precision radiotherapy to more cancer patients in the UK DENVER, Sept. 8, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that GenesisCare, the largest global provider of cancer services across the USA,
4y agoVRAYViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer PatientsPR NewswireThis approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART DENVER, Sept. 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that the company's MRIdian MRI-Guided Radiation Th
4y agoVRAYVA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy ServicesPR NewswireThis is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment. DENVER, Aug. 23, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the VA Houston Healthcare System has
4y agoVRAYNational Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patientsPR NewswireLargest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System CLEVELAND, Aug. 11, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that the National Cancer Center Hospital
4y agoVRAYViewRay Selects Denver for HeadquartersPR NewswireInnovative cancer therapy company to leverage Colorado bioscience talent resources DENVER, Aug. 8, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY), a medical device company that designs, manufactures, and markets the MRIdian® radiation therapy syste
4y agoVRAYViewRay, Inc. (VRAY) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsVRAY earnings call for the period ending June 30, 2022.
4y agoVRAYCentre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy SystemPR NewswireRepresents the first in Lille, France to Bring the Benefits of Precision Radiation Therapy to the Hauts de France Region CLEVELAND, July 29, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that Centre Oscar Lambret has selected a MRIdi
4y agoVRAYSaitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy SystemPR NewswireCLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that Saitama Medical University International Medical Center has purchased a MRIdian MRI-Guided Radiation Therapy System to complete its newly built comprehensive cance
4y agoVRAYViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022PR NewswireCLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, August 2, 2022 at 4:30
4y agoVRAYVA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy ServicesPR NewswireRepresents Second VA Hospital to Offer MRIdian MRI-guided Radiation Therapy Cancer Treatment Directly to Veterans CLEVELAND, June 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the VA Ann Arbor Healthcare System (VAAAHS) has s
4y agoVRAYShin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation TherapyPR NewswireCLEVELAND, June 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy (SMART)
4y agoVRAYHenry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i SystemPR NewswireNew MRIdian A3i features will enable the Henry Ford team to streamline on-table workflow, reduce treatment times, and expand clinical utility to brain treatments CLEVELAND, June 2, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that
4y agoVRAYClinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022PR NewswireRetrospective analysis shows MRIdian's small treatment margins enabled by adaptation and real-time tracking and automated beam control may allow for ablative radiation with minimal toxicity in hard to treat lung lesions CLEVELAND, May 10, 2022 /PRNewsw
4y agoVRAYMRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology MeetingPR NewswireViewRay celebrates 10-years as the first and only company to offer real-time tissue tracking with automatic beam gating and will host a lunch symposium highlighting new MRIdian A3i features CLEVELAND, May 6, 2022 /PRNewswire/ -- ViewRay, Inc. (NASD
4y agoVRAYViewRay Announces First Quarter 2022 ResultsPR NewswireCLEVELAND, May 5, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Total revenue for the first quarter 2022 was approximately
4y agoVRAYViewRay, Inc. (VRAY) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsVRAY earnings call for the period ending March 31, 2022.
4y agoVRAYUCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy SystemPR NewswireMRIdian will be the First MRI-Guided Radiation Therapy System at the UCI Chao Family Comprehensive Cancer Center facility opening in late 2023 CLEVELAND, May 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced that UCI Health has purcha